Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 27, 2023

Talking Automation in Fill/Finish and Cell & Gene Therapies with James Rorke (INTERPHEX 2023)

James Rorke, vice-president, operations, Steriline North America, discusses the benefits of automation in fill/finish operations.

James Rorke, vice-president, operations, Steriline North America, discusses the advantages of automation in fill/finish, particulary for low volume, high quaility products such as cell and gene therapies, for which minimizing product loss is crucial.

For more INTERPHEX 2023 video content, check this page for updates.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.